Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

Rodgers, Gail L.; Esposito, Susanna; Principi, Nicola; Gutierrez-Brito, Maricruz; Díez-Domingo, Javier; Pollard, Andrew J.; Snape, Matthew D.; Martinón-Torres, Federico; Gruber, William C.; Patterson, Scott D.; Thompson, Allison; Gurtman, Alejandra; Paradiso, Peter R.; Scott, Daniel A.

doi:10.1016/j.vaccine.2013.08.009

Cited by 16 publications

(17 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Children receiving a 3+1 schedule, reached higher levels of antibodies after the primary vaccination compared to our study, yet all schedules had similar high seroprotection levels after completion. Nevertheless, we report similar antibody titers after a short primary schedule as do Rodgers et al 13 in their comparative overview on different priming schedules with PCV 13. Higher response rates are reported for serotype 4 but similar lower rates for serotype 23F.…”

Section: Discussionsupporting

confidence: 87%

Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy

Maertens

Burbidge

Damme

et al. 2017

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: Maternal immunization with a tetanus, diphtheria and acellular pertussis (Tdap) vaccine may blunt infant pneumococcal immune responses after a primary series of vaccines. Methods: As part of a prospective controlled cohort trial of Tdap (Boostrix; GSK Biologicals, Rixensart, Belgium) vaccination in pregnancy, infants born to vaccinated mothers and controls were immunized at 8 and 16 weeks and 12 months of age with 13-valent pneumococcal conjugate vaccine (Prevenar13; Pfizer, Wyeth, United States). Sera were tested for pneumococcal antibody concentrations against vaccine serotypes following primary and booster immunization. Results: Geometric mean concentration of antibodies to serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14 and 19A was significantly lower after 2 doses of Prevenar13 vaccine in the offspring of the mothers vaccinated in pregnancy. This blunting effect disappeared after a booster dose at 12 months of age, except for serotypes 1 and 4. Despite this blunting, the percentage of children achieving the threshold of protection of 0.35 µg/mL was comparable in the vaccine and the control group both after primary and booster vaccination with only a significant lower rate of seroprotection in the vaccine group for serotype 3 after primary vaccination. After booster vaccination, seroprotection rates increased further for serotypes 3, 5, 6B, 9V and 23F. Conclusions: The present results indicate a blunting effect after primary vaccination for some serotypes resolving after booster vaccination. Seroprotection rates were comparable both after primary and booster vaccination, except for serotype 3 with a significant lower seroprotection rate in the vaccine group after primary vaccination.

show abstract

Section: Discussionsupporting

confidence: 87%

Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy

Maertens

Burbidge

Damme

et al. 2017

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…Keinenger et al compared the immunogenicity of PCV13 and PCV7 administered on the 3 + 1 schedule and found that after both the primary series and the booster dose, 100% (95% CI: 96.2-100 and 96.3-100, respectively) of children vaccinated with PCV13 had achieved OPA titers ‡8 compared with 17 and 68.1% (95% CI: 10.1-26.2 and 57.5-77.5, respectively) of those given PCV7 [10] achieving the same results. Similar data were obtained with OPA titers ‡8 in >95% of cases after both the primary series and the booster dose were reported by Rodgers et al, who analyzed a number of studies in which children vaccinated with PCV13 according to the 2 + 1 schedule were included [14].…”

supporting

confidence: 84%

“…In a recent post-licensure, indirect cohort study, an antibody concentration against serotype 19A of 1 mg/ml was shown to be adequate to prevent most of the IPD cases due to this serotype [37]. This antibody level was in the range of values produced by PCV13 after both the infant series and the booster dose, independent of the schedule used, as clearly shown by Rodgers et al, who analyzed several immunogenicity studies in which PCV13 was administered on the 2 + 1 schedule [14] and by several authors who have studied PCV13 on the 3 + 1 schedule [38][39][40]. Conversely, the very good results shown by some of the studies that have evaluated PCV10 are surprising and difficult to explain when the putative correlate of protection for serotype 19A and the amount of functioning cross-reactive antibodies produced by conjugate serotype 19F included in PCV10 are considered.…”

Section: Expert Commentarymentioning

confidence: 89%

The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease

Principi

Esposito

2015

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

The circulation in the community of pneumococcal serotype 19A, a highly invasive and frequently extremely resistant pneumococcal strain, has increased the focus on methods to control its presence and effect. Two vaccines have been developed: the 10-valent pneumococcal conjugate vaccine (PCV10) and the 13-valent pneumococcal conjugate vaccine (PCV13). Available data indicate that PCV13 is highly effective in reducing the risk of serotype 19A invasive pneumococcal disease (IPD) in both vaccinated children and unvaccinated adults. Positive data have also been published for PCV10 that suggest that the conjugated serotype 19F included in the vaccine could evoke a cross-reactive antibody response with serotype 19A. However, a great number of invasive pneumococcal disease (IPD) cases are associated with serotypes not included in either of the vaccines, and preparation of a vaccine containing all the serotypes is unrealistic. Protein vaccines are the real future to definitively reduce the pneumococcal disease burden.

show abstract

“…67 In these countries, administration of a booster dose may be especially important because immune responses to PCV, particularly to serotypes 6B and 23F, may be lower after 2 infant doses compared with 3 infant doses. 70 Vaccine uptake and compliance with the pediatric immunization program and a catch-up program are important to maximize herd protection in countries with a 2 + 1 schedule; this could contribute to protection in vaccinated children during the interval between the second infant dose and the toddler dose. Findings from the parental survey suggest that timely and adequate vaccination (ie, timely completion of primary series and booster doses) is a concern in some countries.…”

Section: Importance Of Vaccine Uptake and Schedule Adherencementioning

confidence: 99%

Evolving Role of 13-valent Pneumococcal Conjugate Vaccine in Clinical Practice

Azzari¹,

Martinón-Torres²,

Schmitt

et al. 2014

Pediatric Infectious Disease Journal

Self Cite

View full text Add to dashboard Cite

Since the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), PCVs with extended coverage have become available, and there is emerging global evidence that these vaccines, in particular PCV13, have further reduced rates of invasive pneumococcal disease compared with PCV7. The present article aims to address emerging topics related to PCV13 use in routine clinical practice; specifically: (1) the potential role of high-valent PCVs in reducing pneumococcal disease burden; (2) the impact of PCVs on nasopharyngeal carriage and how this may contribute to reductions in otitis media and pneumonia, as well as the prevalence of resistant pneumococcal strains; (3) new PCV13 indications and (4) importance of schedule adherence for PCV in the prevention of cases of vaccine serotype-specific invasive pneumococcal disease. The beneficial effects of PCVs in protecting individuals from a wide spectrum of pneumococcal diseases can be increased by improving the vaccine coverage and adhering to the recommended vaccination schedules. There is increasing evidence that PCV13 has reduced much of the post-PCV7 burden of pneumococcal diseases in the pediatric community, including reducing pneumococcal colonization and the incidence of invasive pneumococcal disease and mucosal diseases. This has also led to a reduction in antibiotic-resistant pneumococcal diseases. The role of PCV13 in clinical practice is evolving, with PCV13 now available for children and adolescents between the ages of 6 weeks and 17 years, thus ensuring that children in all age groups can be protected against vaccine-serotype pneumococcal diseases. Continued surveillance is warranted to monitor the impact of PCV13 on disease burden.

show abstract

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

Cited by 16 publications

References 61 publications

Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy

Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy

The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease

Evolving Role of 13-valent Pneumococcal Conjugate Vaccine in Clinical Practice

Contact Info

Product

Resources

About